THE HDL STORY: TIME TO RECONSIDER?
EAS Academy, John Chapman, 272735
THE IMMUNE SYSTEM: THE NEXT GAME-CHANGER?
EAS Academy, Matthias Nahrendorf, 272733
SYSTEM-LEVEL ANALYSES OF INFLAMMATORY AND REPAIR MACROPHAGES REVEAL AN INTEGRATED CIRCUITRY OF LIPID AND EPIGENOMIC CHANGES
EAS Academy, Laszlo Nagy, 272732
CLINICAL EXPERIENCE WITH BEMPEDOIC ACID
EAS Academy, Christie Ballantyne, 272731
PHARMACOLOGY OF BEMPEDOIC ACID
EAS Academy, Giuseppe Danilo Norata, 272730
THE GENETIC EVIDENCE FOR INHIBITING THE CHOLESTEROL SYNTHESIS PATHWAY TO CONTROL LDL CHOLESTEROL
EAS Academy, Brian Ference, 272729
REDUCE-IT: AN IN DEPTH ANALYSIS
EAS Academy, Christie Ballantyne, 272725
OMEGA 3 FATTY ACIDS: BIOLOGICAL FUNCTIONS
EAS Academy, Alexandros Tselepis, 272723
Microbiome: A New Theory of Atherosclerosis?
EAS Academy, Thomas Luscher, 272719
ESTIMATING RISK: WHAT’S NEW?
EAS Academy, Kausik Ray, 272718
ESTIMATING RISK: WHAT’S NEW?
EAS Academy, Ian Graham, 272717
THE GENETIC BURDEN IN CVD
EAS Academy, Heribert Schunkert, 272716
WHAT IS THE EVIDENCE FOR UPFRONT COMBINATION?
EAS Academy, Michel Farnier, 272708
Inflammation, Inhibition and Atherothrombosis
EAS Academy, Paul Ridker, 272705
Modified lipids and lipoproteins
EAS Academy, Joseph L. Witztum, 272704
Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis
EAS Academy, Jan Borén, 272703
A Journey From Plaque to Pate
EAS Academy, Helen Hobbs, 272699
EFFICACY AND SAFETY OF NUTRACEUTICALS
EAS Academy, Maciej Banach, 272694
POSSIBILITIES FOR NUTRIGENETICS AND NUTRACEUTICALS IN CVD PREVENTION
EAS Academy, Jogchum Plat, 272693
DIFFERENT APPROACHES TO LDL LOWERING: AN OVERVIEW OF OPTIONS INCLUDING NUTRITION, FOOD SUPPLEMENTS, AND DRUG THERAPY
EAS Academy, John Chapman, 272692
Adaptive Immunity: T cells and B cells
EAS Academy, Ziad Mallat, 234784
Innate immunity: Inflammasome
EAS Academy, Eicke Latz, 234783
Regulation of lipid metabolism by inflammation
EAS Academy, Laurent Yvan-Charvet, 234782
LDL retention
EAS Academy, Jan Borén, 234781
2016 ESC/EAS guidelines for the management of dyslipidaemias-risk prediction and treatments targets
EAS Academy, Olov Wiklund, 233810
New and old lipid-lowering drugs
EAS Academy, Lale Tokgozoglu, 233809
What have Mendelian Randomization studies revealed for cardiovascular disease beyond lipids?
EAS Academy, Marianne Benn, 233808
Causality of lipid traits for other diseases
EAS Academy, Ruth Frikke-Schmidt, 233807
The case of lipoprotein(a) and cardiovascular disease
EAS Academy, PIA R. KAMSTRUP, 233806
Using genetics to predict drug effects and adverse events
EAS Academy, Anne Tybjaerg-Hansen, 233805
The case for triglyceride-rich lipoproteins and cardiovascular disease
EAS Academy, Borge Nordestgaard, 233804
Concepts of Mendelian randomization
EAS Academy, Shah Ebrahim, 233803
Genetic disorders of lipid metabolism - with special focus on familial hypercholesterolaemia
EAS Academy, Kees Hovingh, 233802
Biology of lipid metabolism
EAS Academy, Patrick Rensen, 233801
Global burden of cardiovascular disease and contribution of risk factors
EAS Academy, Gregory Roth, 233800
EAS Clinical Lipidology Essentials
EAS Academy, EAS, 226229
Module 1: Epidemiology. Development of cardiovascular disease in different populations
EAS Academy, Annika Rosengren, 226230
Module 2: Mendelian randomization approach to understand effect of lipoprotein in causing disease
EAS Academy, Anne Tybjaerg-Hansen, 226231
Module 3: Basics in Lipoprotein Metabolism
EAS Academy, Jan Borén, 226232
Module 4: Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 226233
Strategies to treat vulnerable plaques
EAS Academy, David Erlinge, 217777
Novel therapeutic approaches using antisense inhibition (TBD)
EAS Academy, Joseph L. Witztum, 217776
Lessons from genetics: risk-score and novel candidates
EAS Academy, Brian Ference, 217775
Atherothrombosis; from pathogenesis to treatment
EAS Academy, Steffen Massberg, 217774
NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM
EAS Academy, Vinay Sachdev, 217771
GENETIC REGULATION OF HDL CHOLESTEROL LEVELS DURING SEPSIS
EAS Academy, Liam Brunham, 217769
Lipid Signaling pathways in physiology and disease
EAS Academy, Peter Tontonoz, 217768
The role of bile acids in cholesterol homeostasis
EAS Academy, Albert K. Groen, 217767
Panel Discussion
EAS Academy, Session Speakers, 218366
The ideal patient for PCSK9
EAS Academy, J. Wouter Jukema, 217755
Combination therapy: When and how
EAS Academy, Michel Farnier, 217764
How to control atherogenic dyslipidaemia
EAS Academy, Henry Ginsberg, 217763
Panel Discussion
EAS Academy, Session Speakers, 218372
PCSK9 Inhibition in high risk patients
EAS Academy, Gabriel Steg, 217754
Lipids, inflammation and CV risk
EAS Academy, Erik Stroes, 217753
New targets for controlling dyslipidaemias and atherosclerosis: chair
EAS Academy, Paolo Parini, 217757
Silencing genes, new targets
EAS Academy, Sotirios Tsimikas, 217758
APO B CONTAINING LIPOPROTEINS A BETTER TARGET FOR CV RISK REDUCTION?
EAS Academy, Brian Ference, 217762
Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia
EAS Academy, Marja-Riitta Taskinen, 217750
Reality check: Can we get to goals in guidelines?
EAS Academy, Ulrich Laufs, 217747
Will inhibiting thrombus formation prevent acute coronary syndromes?
EAS Academy, Stephan Gielen, 217746
Will aggressive LDL reduction prevent atherosclerosis?
EAS Academy, Alberico Luigi Catapano, 217744
RNA editing controls atherosclerosis
EAS Academy, Stefanie Dimmeler, 217741
Shifting concepts in the description of the “vulnerable plaque”
EAS Academy, Gerard Pasterkamp, 217740
Defective Inflammation Resolution in Atherosclerosis: Mechanisms and Therapeutic Opportunities
EAS Academy, Ira Tabas, 217739
Neoatherosclerosis from a pathologist's point of view
EAS Academy, Renu Virmani, 217738
Recent evidence for the prevention of atherosclerotic cardiovascular diseases
EAS Academy, Petri Kovanen, 221468
A PLASMA CIRCULATING MIRNAS PROFILE PREDICTS TYPE 2 DIABETES MELLITUS AND PREDIABETES: FROM THE CORDIOPREV STUDY
EAS Academy, Antonio Camargo, 217735
DEVELOPMENT OF ANTISENSE DRUG TARGETING PCSK9
EAS Academy, Mariko Harada-Shiba, 217734
Are we ready to test the Lp(a) Hypothesis?
EAS Academy, Sotirios Tsimikas, 217732
Nanomedicine as novel atherosclerosis therapy
EAS Academy, Willem J.M. Mulder, 217731
Incremental value of established therapies for dyslipidaemic patients
EAS Academy, Luis Masana, 217811
Reducing cholesterol by dietary means
EAS Academy, Eric Bruckert, 217724
DIETARY FAT VS CARBOHYDRATES
EAS Academy, Gabriele Riccardi, 217723
Food4me: the experience
EAS Academy, Michael Gibney, 217722
LDL and apoB-lipoprotein as causative agents in ASCVD
EAS Academy, Chris Packard, 217726
PCSK9 inhibition the clinical evidence
EAS Academy, Peter Sever, 217727
A contemporary approach to dyslipidaemias, PCSK9 inhibition
EAS Academy, Ulf Landmesser, 217728
KEYNOTE LECTURE: Chair
EAS Academy, Petri Kovanen, 217718
Anti-Inflammatory Therapy for Atherosclerosis - Theory and Practice
EAS Academy, Peter Libby, 217719
Genes can hurt you to develop CVD beyond classical risk factors
EAS Academy, Stefano Romeo, 217716
Mining the blood for new cardiometabolic markers
EAS Academy, Robert Gerszten, 217714
High-resolution lipoprotein phenotypes and cardiovascular outcomes
EAS Academy, Samia Mora, 217713
Is there need to revise goals from lipid lowering?
EAS Academy, Ulf Landmesser, 217710
Stress, behavior and cardiovascular disease
EAS Academy, Viola Vaccarino, 217709
Lessons from epidemiology and environmental CVD risk factors
EAS Academy, Salim Yusuf, 217708
Imaging and CVD risk estimation (population studies)
EAS Academy, Valentin Fuster, 217707
Lipoprotein Metabolism
EAS Academy, Arnold von Eckardstein, 221467
The Anitschkow Lecture - Genetics of cardiovascular disease: from ugly duckling to beautiful swan
EAS Academy, Anne Tybjaerg-Hansen, 217704
Science versus reality in long term management: Time for a paradigm shift?
EAS Academy, Lale Tokgozoglu, 217702
Optimising therapy through cardiac rehabilitation
EAS Academy, Anselm Gitt, 217701
Patient journey after acute coronary syndromes: can we improve outcomes?: Chair
EAS Academy, Peter Toth, 217699
Hospital management after acute coronary syndromes: Is the risk over ?
EAS Academy, Jose L. Zamorano, 217700
Molecular and biochemical mechanisms involved in the protective effect of Mediterranean diet against atherosclerosis
EAS Academy, Alvaro Hernaez, 217696
Effects of the different dietary fatty acids on health: focus on PUFA n-6. New evidences and controversies
EAS Academy, Andrea Poli, 217695
Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil
EAS Academy, Emilio Ros, 217694
Diet and CVD the epidemiological view
EAS Academy, Salim Yusuf, 217693
The multifaceted aspects of CV prevention: from nutrition to therapy: Chair
EAS Academy, Prof. Alberico L. Catapano, Dr. Alberto Mello e Silva & Dr. Xavier Pinto, 218363
Systemsbiology and cardiovascular disease
EAS Academy, Jörg Menche, 202892
Gut microbiome and atherothrombosis
EAS Academy, Christoph Reinhardt, 202891

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings